Introduction
============

Several types of high-affinity binding sites for benzodiazepines (BDZ) have been described in the central nervous system (CNS) and in peripheral organs on the basis of their different affinity for radiolabeled ligands ([@b26]; [@b31]). The central receptors, almost all of which are found in the cortex, limbic areas, and cerebellum ([@b42]), are mainly labeled by flumazenil, whereas the peripheral type of BDZ receptors are identified specifically by Ro 5-4864 and PK 11195 ([@b22]). The most abundant sources of peripheral BDZ receptors are kidneys, lungs, ovaries, testes, and adrenal glands, but they are also present in the CNS, particularly in glial cells ([@b2]).

From a functional point of view, while the salient feature of the central BDZ receptor is coupling with the GABA-A receptor complex and facilitation of GABA transmission ([@b8]), the peripheral type lacks this association and is localized to the mitochondrial outer membrane ([@b1]; [@b38]). The most exhaustive hypothesis on the role of this receptor is the one suggesting a role in steroidogenesis, since in adrenals it has been demonstrated that it mediates the translocation of cholesterol from the outer to the inner mitochondrial membrane and is involved in the chain cleavage of cholesterol ([@b27]; [@b32]). Therefore, it is supposed that peripheral BDZ receptors subserve the same function in nonsteroidogenic tissues; particularly in glial cells, which have been shown to synthetize steroids, such as pregnenolone and progesterone and its derivatives called neurosteroids, which are able to alter the electrical properties of neuronal membranes and thus the firing patterns of neurons ([@b1]; [@b17]; [@b19]; [@b41]). Such compounds, in turn, strongly modulate the GABA-A receptor complex and thereby the stress response ([@b34]). It is noteworthy that different stress paradigms in animals produce changes in peripheral BDZ receptors ([@b10], [@b11]; [@b30]).

Furthermore, the peripheral BDZ receptor is involved in a variety of other actions, such as control of cell proliferation, chemiotaxis, and contractility of the myocardium ([@b36]; [@b21]; [@b39]; [@b12]).

The presence of these receptors in blood cells, such as platelets or lymphocytes, which undergo the same regulation and changes as in other tissues, particularly in the brain ([@b10]), has offered a peripheral tool for studies in humans. Stressful situations, such as sitting an exam ([@b20]) or a parachute-training course ([@b9]), influence the density of receptors as an acute stress seems to provoke an up-regulation, while a repeated stress provokes a down-regulation ([@b11]; [@b30]; [@b17]; [@b19]; [@b34]).

The literature is also reporting changes of peripheral BDZ receptors in different psychiatric disorders, such as generalized anxiety disorder (GAD), social phobia, panic disorder, obsessive-compulsive disorder (OCD), Alzheimer's disease, and schizophrenia ([@b15]; [@b5]; [@b35]; [@b24]; Bidder et al 1997), while no information is available in patients with mood disorders, in spite of evidence that stress systems are altered in these diseases (for review, see [@b7]), and there is frequent comorbidity with various anxiety disorders ([@b6]; [@b16]; [@b37]).

To further clarify this issue, we investigated peripheral BDZ receptors by the specific binding of ^3^H-PK 11195 in platelets of patients suffering from bipolar disorder, according to strict DSM-IV criteria, and in a similar group of healthy control subjects.

Subjects and methods
====================

Subjects
--------

Twenty outpatients (12 male and 8 female, between 23 and 55 years of age, mean ± SD: 35.7 ± 11.4) affected by bipolar disorder were included in the study. Diagnoses were made by trained psychiatrists according to the Structured Clinical Interview (SCID) for DSM-IV (APA 1994; [@b14]). Twelve patients were bipolar II (5 were depressed, 7 euthymic) and 8 were bipolar I (all in the euthymic phase). Five patients out of the total 20 were drug-free and fifteen were taking mood stabilizers (5 lithium salts, 8 valproate, 1 gabapentin, 1 lamotrigine). Of the total 5 depressed patients, 3 were taking antidepressants (1 clomipramine, 1 sertraline, 2 citalopram, 1 fluvoxamine), drugs that do not interfere with ^3^H-PK 11195 binding parameters. No patient was taking BDZs.

The controls included 20 healthy drug-free subjects (10 male and 10 female, between 25 and 45 years of age, mean ± SD: 28.6 ± 5.4), with neither family nor personal history of any major psychiatric disorder, as recorded by the SCID.

In addition, both patients and controls had no physical illness, as documented by a physical exam and blood and urine tests. Informed consent was obtained from all subjects of the study, which was approved by the Ethics Committee at Pisa University.

Methods
-------

Thirty milliliters of venous blood was drawn from fasting subjects between 8 am and 10 am, collected into plastic tubes containing 5 mL of anticoagulant (2.2% sodium citrate and 1.2% citric acid), and centrifuged at 150 × *g* for 15 min at 23 °C. Platelet-rich-plasma was collected and centrifuged at 1500 × *g* for 15 min at 23 °C. The drained platelet pellet was frozen at −80 °C until the binding assay, which was carried out within 2 weeks. Prior to the binding assay, the platelets were lysed and homogenized in 12 mL buffer (50 mmol/L Tris HCl, pH 7.4) using an Ultra Thurrax homogenizer for 5 s at 2/3 full speed and then centrifuged at 49 000 × *g* for 15 min at 4 °C. This procedure was immediately repeated. The membranes were resuspended in 12 mL of 50 mmol/L tris HCl and used for binding studies.

The binding of ^3^H-PK 11195 to platelet membranes was performed according to a slight modification of the method of [@b15]. Four hundred microliters of membrane suspension (50 μg protein) was incubated with 20 μL of PK 11195 (specific activity: 82.4 Ci/mmol NEN, England,) at final concentrations ranging between 1 and 8 nmol/L, and 50 mmol/L Tris HCl buffer, pH 7.4, in a total volume of 500 μL. Non-specific binding was determined in the presence of 10 μ mol/L unlabelled PK 11195 (Sigma, Milan, Italy). The incubation lasted for 90 min at 0 °C and was stopped by the addition of 5 mL of ice-cold incubation buffer and filtration under vacuum over Whatman GF/B filters. The filters were washed three times with 5 mL of the same buffer, placed in vials and counted in 4 mL of scintillation cocktail in a liquid scintillation counter.

The data were evaluated by Scatchard analysis to obtain the maximal number of binding sites (Bmax, fmol/mg protein) and their affinity to ^3^H-PK 11195 as expressed by the equilibrium dissociation constant (Kd, nmol/L), by means of microcomputer programs (EBDA and LIGAND) ([@b25]).

Protein concentration was determined according to the method of [@b33]. The difference between the groups was measured by means of Student's test (un-paired, two-tailed). The effect of age and sex on biological parameters was assessed by means of covariance analysis, and the possible correlations between biological findings and psychopathological data were analyzed according to Pearson's method, with Personal Computer programs (StatView V, SSPS) ([@b28]).

Results
=======

The results showed that the Bmax (mean ± SD, fmol/mg protein) was 6263 ± 1960 in bipolar disorder patients and 4855 ± 1621 in the control subjects, statistically higher in the first than in the other group (t-test: p \< 0.01). On the contrary, the Kd (mean ± SD, nmol/L) did not show any difference, with the values 5.43 ± 1.53 in the patients and 5.33 ± 1.92 in the control subjects. No difference between patients with bipolar I and bipolar II disorder was detected.

No age or sex effect was observed, and no relationship between biological parameters and clinical features was noticed.

Discussion
==========

The major finding of this study is the presence of an increased density (Bmax) of peripheral BDZ receptors in platelets of patients with bipolar disorder, as compared with healthy controls, with no associate change in the dissociation constant. No difference between bipolar I and bipolar II patients was detected. Since a significant increase in Kd values has been reported in subjects over 70 years of age ([@b23]), we controlled this variable in the groups who were selected on the basis of a limited age range, and we observed no effect. Similarly, no sex-related influence on the binding of ^3^H-PK-11195 was noticed. Although no seasonal change in the binding has been observed to date, we performed all the blood sample analysis in a limited period of the year (from March to May).

Our results in patients with bipolar disorder are the first report in this group of patients; however, it must be mentioned that due to the small sample size it was not possible to perform reliable statistical analyses or to ascertain the real impact, if any, of the different phases of the illness on ^3^H-PK 11195 binding.

Previously, patients with panic disorder, social phobia, or GAD have been shown to have a low density of PK11195 binding sites ([@b40]; [@b13]; [@b18]). In addition, in patients with GAD, the density of peripheral BDZ receptors would return towards the values found in healthy controls after treatments with BDZs ([@b13]). With regard to patients with OCD, the ensuing findings are quite controversial: patients with a chronic course seem to be characterized by no change in the binding of ^3^H-PK11195 ([@b24]), while patients with an episodic course would show a decreased density of ^3^H-PK11195 binding sites ([@b35]). In some cases, decreased peripheral BDZ receptor density in lymphocytes has been showed to be paralleled by similar changes in mRNA levels ([@b35]; [@b29]).

The modifications observed in platelets should reflect similar changes in other organs rich in peripheral BDZ receptors, such as glial cells and pituitary at the level of the CNS, heart, and kidney, as it has been demonstrated in rats that underwent inescapable tail shock ([@b10]). Such changes might be linked with a general membrane abnormality, as it has been proposed for Alzheimer's dementia ([@b43]), or with abnormalities in endogenous ligands acting at their level, or represent a non-specific sign of stress, as it has been demonstrated that peripheral BDZ receptor density is significantly correlated with changes in corticosteroid levels ([@b29]).

In any case, it is puzzling that bipolar patients with no comorbid disorder have an increased density of peripheral BDZ receptors, at variance with patients with other psychiatric conditions, mainly of the anxiety spectrum. It is not possible as yet to conclude whether the changes in peripheral BDZ receptors represent a primary phenomenon related to the etiology or pathophysiology of the disease, or alternatively are secondary to changes in other systems, such as those regulating the stress response.

Future studies should aim to explore peripheral BDZ receptors in patients with other mood disorders with and without comorbid conditions in order to clarify whether eventual changes at their level might be helpful in confirming diagnostic categories or in characterizing different comorbidity patterns.
